Different embryo-fetal toxicity effects for three VLA-4 antagonists

Area of Science:

• Developmental toxicology
• Pharmacology
• Immunology

Background:

• Very late antigen 4 (VLA-4) is crucial for cell-cell interactions during development.
• Genetic deficiencies in VLA-4 or its ligand VCAM-1 lead to embryonic lethality due to abnormal development.
• Understanding VLA-4 antagonist teratogenicity is vital for drug safety.

Purpose of the Study:

• To evaluate and compare the teratogenic potential of three VLA-4 antagonists: IVL745, HMR1031, and IVL984.
• To identify dose-dependent effects and specific malformations induced by these compounds.
• To assess the safety profile of VLA-4 antagonists during embryonic development.

Main Methods:

• Standard embryo-fetal developmental toxicity studies were conducted in rats and rabbits via subcutaneous administration.
• IVL984 was also tested in mice.
• Fetuses underwent external, visceral, and skeletal examinations to identify developmental abnormalities.

Main Results:

• IVL745 exhibited no significant maternal or fetal toxicity at tested doses.
• HMR1031 caused maternal toxicity and slight fetal effects (e.g., reduced body weight, sternebral defects) at high doses.
• IVL984 was a potent teratogen, inducing embryo lethality, cardiac malformations (including spiral septal defects), and skeletal defects at low doses, with minimal maternal toxicity except for abortions in rabbits.

Conclusions:

• IVL745 is not teratogenic.
• HMR1031 demonstrates mild embryo-fetal toxicity at maternally toxic doses.
• IVL984 is a potent teratogen, causing significant developmental abnormalities, including cardiac malformations and embryo lethality, across multiple species at non-maternally toxic doses.